[Form 4] Vivani Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vivani Medical Director Wilford Dean Baker received a non-qualified stock option grant on June 24, 2025, as part of the company's Non-Employee Director Compensation Policy. The grant details include:

• 35,135 options to purchase common stock
• Exercise price of $1.27 per share
• Expiration date of June 23, 2035
• Vesting occurs in full on either the first grant anniversary or next annual stockholder meeting, whichever comes first

The Form 4 filing, signed by Attorney-in-fact Adam Mendelsohn on June 26, 2025, represents a standard annual director compensation grant. The vesting is contingent on Baker's continued service through the vesting date. This equity compensation aligns the director's interests with those of shareholders through long-term stock ownership potential.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baker Wilford Dean

(Last) (First) (Middle)

C/O VIVANI MEDICAL, INC.

1350 S. LOOP ROAD

(Street)

ALAMEDA CA 94502

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vivani Medical, Inc. [ VANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$1.27	06/24/2025		A		35,135		(1)(2)	06/23/2035	Common Stock	35,135(2)	$1.27(2)	35,135(2)	D

Explanation of Responses:

1. Annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy.

2. The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date.

Remarks:

Exhibit 24 Power of Attorney

	/s/ Adam Mendelsohn, Attorney-in-fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did VANI director Wilford Dean Baker receive on June 24, 2025?

Wilford Dean Baker received 35,135 non-qualified stock options with an exercise price of $1.27 per share. These options were granted as part of VANI's Non-Employee Director Compensation Policy.

When do the stock options granted to VANI's director Baker vest?

The stock options vest in full on the earlier of either (i) June 24, 2026 (the first anniversary of the grant) or (ii) VANI's next annual meeting of stockholders, subject to Baker's continued service through such date.

What is the expiration date for VANI director Baker's newly granted stock options?

The stock options expire on June 23, 2035, ten years after the grant date.

How many VANI shares can Director Baker purchase with the new stock options?

Director Baker can purchase 35,135 shares of VANI common stock at an exercise price of $1.27 per share through these newly granted stock options.

Who signed the Form 4 filing for VANI director Wilford Dean Baker?

The Form 4 was signed by Adam Mendelsohn as Attorney-in-fact for Wilford Dean Baker on June 26, 2025.